The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...

The FDA has set a goal date of Aug. 27, 2025. If approved, the therapy would be branded as Lytenava and be the first ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

The green light comes on the back of the phase 3 ARCHWAY trial which showed that Susvimo was equivalent to monthly Lucentis injections at maintaining vision in patients over 40 weeks, with 98% of ...

Researchers said the savings from reducing ranibizumab injections “more than offset” the cost of providing radiation using robots. The estimated mean saving per patient in the trial was £565 ...

The average number of intraocular injections administered before aflibercept ... modality for patients with AMD who are resistant to ranibizumab. While anatomic success including the effect ...

he was one of five chosen for a clinical trial of Lucentis, a new drug just approved by the FDA to treat the wet form of the disease. Each month for 2 years Verle received an injection directly ...

Ranibizumab is a selective vascular endothelial growth factor (VEGF) antagonist, prescribed for neovascular (wet) age-related macular degeneration (AMD- loss of vision) and macular edema following ...

The green light comes on the back of the phase 3 ARCHWAY trial which showed that Susvimo was equivalent to monthly Lucentis injections at maintaining vision in patients over 40 weeks, with 98% of ...